Stats: 3,186,781 members, 7,930,670 topics. Date: Sunday, 25 August 2024 at 03:02 AM |
Nairaland Forum / Aremso's Profile / Aremso's Posts
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (of 91 pages)
![]() |
thehvacservice:. |
![]() |
henrimoto: Expectations on TCRT was merger and acquisition not even their FS 1 Like |
![]() |
henrimoto: They have something in pipeline, waiting period is always tough. I started watching TCRT when it was 0.40 they cancelled their pipeline then it fell to 0.15 I started buying at this level after all life itself na risk. I average down to 0.11. Let see how it will play out. If it turns out good them I will use the gain to load more of PIRS to average down wella so it will be easier to exit with little or no loss if it doesn't work fine but am optimistic it will 1 Like |
![]() |
TCRT might move today Not investment advice! 1 Like |
![]() |
henrimoto: This keep moving silently! Gained 20% on Friday with their good q3 1 Like |
![]() |
henrimoto: I have sold at 34-37$ leaving 9units left. Have removed my Capital leaving the gain then when the pay the CVR I will add it to my trading account. 1 Like |
![]() |
henrimoto: 8units 1 Like |
![]() |
FREQ +57% 1 Like |
![]() |
sgtponzihater1: Amen bro |
![]() |
Update on FREQ: RS of of 1:50 CVR payment thinking of least 0.50$ Qualification date - 2/11/2023 Payment date 8/11/2023 New merged name on NASDAQ - KORRO Bio Starting trading date for new KORRO- 6/11/2013 Price to be listed should be $15 according to my calculations Shares outstanding post merger- 8m+ units from 36.5munits premerger Can we buy it now ? NO The stock can do 25-30$ with time cos new KORRO has a lot in their pipeline Wished CVR payment would be around $1 2 Likes |
![]() |
For those in FREQ- the news came late hope it will push the price up on Monday GlobeNewswire UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million Korro Bio, Inc. November 3, 2023 at 8:31 PM·8 min read Korro Bio, Inc. Korro Bio, Inc. Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial Shares to trade on Nasdaq under the ticker “KRRO” commencing on November 6, 2023 CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases, today announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. (Frequency; Nasdaq: FREQ) and the entity formerly known as Korro Bio, Inc. (Korro Bio). The combined company will operate under the name Korro Bio, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “KRRO” on November 6, 2023. ADVERTISEMENT Advertisement Immediately prior to the merger, Korro completed the previously announced $117 million private placement co-led by Surveyor Capital (a Citadel company) and Cormorant Asset Management with participation from Eventide Asset Management, Atlas Venture, NEA, Invus, Point72, Platanus, Qiming Venture Partners USA, MP Healthcare Venture Management, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and additional investors. Following consummation of the transactions, Korro’s cash, cash equivalents and investments of approximately $170 million, after transaction expenses, are expected to fund operations and multiple potentially value-creating milestones into 2026, including advancing its lead product candidate in AATD through a clinical milestone, progression of additional product candidates from the pipeline into the clinic, and demonstrating applicability of the RNA editing platform into several additional tissue types. “This transformative transaction provides us with the capital to demonstrate the potential of our proprietary RNA editing platform, OPERATM, to develop novel genetic therapies that hold new promise for patients and caregivers,” said Ram Aiyar, PhD, Chief Executive Officer of Korro. “We have a deep pipeline with multiple high-value targets, with an initial focus on progressing the lead product candidate in AATD into the clinic. We intend to leverage our learnings from genetics and pharmacology to bring groundbreaking therapeutic options for patients based on generating de novo single nucleotide variants. We appreciate the support and confidence of our investors and the commitment of our dedicated employees as we enter our next phase as a public company.” Korro’s RNA editing approach involves co-opting ADAR, an endogenous editing system, via engineered oligonucleotides to introduce precise edits to RNA. Korro’s proprietary platform enables the iterative optimization of the editing efficiency of its product candidates using a combination of ADAR biology, chemistry and machine learning expertise. Using this approach, Korro can edit the transcriptome with high efficiency and specificity. Korro’s OPERA platform enables a broad pursuit of indications with an initial focus on six potential programs, all wholly owned, that either correct the mutation or create de novo protein variants that can address the disease. Korro's lead program in AATD has demonstrated an increase of normal A1AT protein up to 85% of total A1AT protein in circulation in in vivo preclinical studies, which has the potential of disease-modifying effects and providing a differentiated therapeutic option. ADVERTISEMENT Advertisement Key milestones for the lead program include: Nomination of a development candidate for its AATD program in late 2023 Submission of a regulatory filing in the second half of 2024 The combined company will be headquartered in Cambridge, Massachusetts, and will be led by Ram Aiyar, PhD, Chief Executive Officer of Korro Bio and other members of the Korro Bio management team. The Board of Directors of the combined company will initially be comprised of six members, including Nessan Bermingham (Chairman), Ali Behbahani, Jean-François Formela, David L. Lucchino, Tim Pearson, Ram Aiyar, with an additional independent director to be nominated. 1 Like |
![]() |
9free: My brother pass it ooo not for everyone, I have seen a health stock from 0.16$ rose to $7.10 in just 2 days. Just that bamboo doesn't have the stock, 10k units alone am off us stock for 1 Month when am done pulling my loot out to MF then I will be back, hope I jam such stock on bamboo. Pls NO ONE should near the stock ooo to avoid stories that touch. |
![]() |
henrimoto: Watch TCRT, surged +25% after trading hour I don't know which info brewing about the stock Your DD! 1 Like |
![]() |
henrimoto: Stay off from all of them for now, Health stocks can bring surprises based on FDA approvals or mergers. It will always be difficult for US stocks to rise in my own views because of their system, the system allows u to sell any stock even if u don't own such stock, u can borrow any stock to sell at certain rate from the brokers. 1 Like |
![]() |
Health stocks still my choice currently, HLTH still delivered as expected this week while FREQ has been surging 5-20℅ gain during trading but closing flat once they finalize their merger that resistance of 0.35$ it will brake it hope they can push to 1.30$ |
![]() |
watch this INO If they get FDA approval it can run 440% Your DD! 2 Likes |
![]() |
Why I love Health stocks, this stock- TPST did +2900% in just 2 days upon successful completion of their Cancer drug from 0.20$ to 7.10$ though mad profit taking on going. Wished the stock is on bamboo, I would have made good profits by now. 1 Like |
![]() |
henrimoto: It might be selected stocks of companies with their base in isreal if at all it will have impact, am sure US will not put mouth, is an age long fight and that is how it will be off and on till the coming of Jesus Christ. 1 Like |
![]() |
Watch these: ACRx SGMO Your DD Note: I dentify strong support level 1 Like |
![]() |
NPF data really favours market small today |
![]() |
henrimoto: Twice in a week is ok for me, it has done 0.4120-0.4775 today if I have volumes am ok with twice a week. If I buy yesterday and sell yesterday I will have access to the money on Monday. I will buy and sell on Monday then have access to the fund on Wednesday. 1 Like |
![]() |
henrimoto: Have been watching HLTH strong support at 0.39-0.4120 since around last week with a resistance of 0.45-0.50, 0.55 max. So I I buy let say 1k units at support sell at resistance that is around 50$ it has been doing that almost everyday day. So if I buy more volumes at 0.05$ money will still be made. Has been doing 10% almost everyday then close flat in the evening. Your DD 1 Like |
![]() |
henrimoto: Sure am holding on to my stocks money must be made, have adopted 5cent/volume strategy. Money must be made in US market. Is a Golden Land to build wealth if u strategize well. Have been some how busy and also taking time out to check stocks movements to see the one that will give me the adopted strategy. Money must be made! 1 Like |
![]() |
yok: Apt! We are not here to joke and we don't want anyone here to turn this place to such. |
![]() |
Zagee: Yea it comes once in a while according to the design of God. 2 Likes |
![]() |
Zagee: Yea that was why I still regrets I never knew about US stocks then, health sector most especially created a lot of millionaires in dollars during that time that was why I said before that is a market where u can invest just $500 and it turns $5000. GOTU got to $100 then. It is well, I pray for such great opportunity of generational wealth transfer again! 1 Like |
![]() |
OCGN has formed a double bottom, can take off anytime. Wished to buy more if it come down again. Your DD. Currently doing +10% 1 Like |
![]() |
Don't miss this stock when market tank well GWH, my next non health stock. Your DD. |
![]() |
For those that follows the stocks I call pls I can pull out at anytime so when the stocks have done 50-100% pls pull out to enter another stock there will always be stocks to make money. I don't want anyone to pay any school fees oo cos me sef not ready to pay any school fees. Once the stocks get to resistance and finding hard to move up pls pull the trigger and move. |
![]() |
abuhusna1: Again I repeat go back to your account and watch how those stock are doing and even that $5k is even much, if u have 1k u did shuttle between RBT to TSHA to CGC to fix by now it should be around 4k at least so don't leave it like that else your Capital becomes $1k WarrenBuffet rules must be followed 1- don't losses your Capital 2- don't forget rules 1. 1 Like |
![]() |
In my view, market will still be bloody so cash is king then strike at any opportunity. 1 Like |
![]() |
henrimoto: Bro am out if CGC, RBT, TSHA, HLTH, CGC if it doesn't hold at 85-80c bye Janet going back to 50c HLTH doesn't hold at 70c it doesn't hold at 60c if it brakes 50c going back to 35-38c RBT will do RS so am only holding FREQ for merger, PIRS for possible merger then TCRT. On TCRT once it runs like 20- 50% off I go. I entered OCGN they have a lot of clinical trials in piple line so any announcement will send it high. US stocks no matter how mad it is I will make money by God grace. OCGN has done almost 100% gain, my guy in Australia with deep pocket has Cashed out 1 Like |
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (of 91 pages)
(Go Up)
Sections: politics (1) business autos (1) jobs (1) career education (1) romance computers phones travel sports fashion health religion celebs tv-movies music-radio literature webmasters programming techmarket Links: (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) Nairaland - Copyright © 2005 - 2024 Oluwaseun Osewa. All rights reserved. See How To Advertise. 66 |